

**OPTIMA HEALTH COMMUNITY CARE  
AND  
OPTIMA FAMILY CARE  
(MEDICAID)**

**PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\***

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to **1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is NOT complete, correct, or legible, authorization will be delayed.**

**Drug Requested:** Gilotrif™ (afatinib)

**DRUG INFORMATION:** Complete **all** information below or authorization will be delayed.

**Drug Form/Strength:** \_\_\_\_\_

**Dosing Schedule:** \_\_\_\_\_ **Length of Therapy:** \_\_\_\_\_

**Diagnosis:** \_\_\_\_\_ **ICD Code, if applicable:** \_\_\_\_\_

**CLINICAL CRITERIA:** Check below **ALL** that apply. **ALL** criteria **must** be met for approval. **ALL** documentation, including lab results and/or chart notes (**when required**), **must** be provided or request will be denied.

**Approval Authorization – Six (6) months**

1) Metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations?  Yes  No

**OR**

2) Metastatic squamous MSCLC progressing after platinum-based chemotherapy?  Yes  No

Which platinum-based chemo? \_\_\_\_\_

3) Has patient tested positive for EGFR exon 19 deletions or exon 21 (L858R) substitution mutations with an FDA approved test?  Yes  No

If **YES**, please provide testing results (**Information on FDA-approved tests for the detection of EGFR mutations for NSCLC may be found at <http://www.fda.gov/CompanionDiagnostics>**).

4) Is medication being prescribed by an oncologist or a hematologist?  Yes  No

5) Is patient 18 years of age or older?  Yes  No

6) If female, is patient pregnant or breastfeeding?  Yes  No

**MEDICAL NECESSITY:** Provide clinical evidence/chart notes/documentation that support the use of the requested medication; attach to this request.

(Continued on next page; signature page **MUST** be attached to request form)

(Signature page **MUST** be included with request)

**\*\*Use of samples to initiate therapy *does not meet step edit/ preauthorization criteria.*\*\***

**\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\***

Patient Name: \_\_\_\_\_

Member Optima #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

DEA OR NPI #: \_\_\_\_\_

REVISED/UPDATED: 12/23/2017; 8/20/2018 (Reformatted) 4/11/2019